# An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma

> **NCT00880061** · PHASE1 · TERMINATED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 7 (actual)

## Conditions studied

- Brain Neoplasm
- Glioma

## Interventions

- **DRUG:** IL13-PE38QQR

## Key facts

- **NCT ID:** NCT00880061
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04-07
- **Primary completion:** 2015-06-05
- **Final completion:** 2015-06-05
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2018-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00880061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00880061, "An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00880061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*